Close Menu

NEW YORK (360Dx) – Melbourne, Australia-based Sienna Cancer Diagnostics announced today it has entered an agreement that makes Inside Diagnósticos its exclusive distribution partner for Brazil.

The agreement gives Inside Diagnósticos the right to sell Sienna’s telomerase reverse transcriptase (hTERT) test to pathology labs for use as an adjunct to urine cytology, assisting pathologists and urologists in the diagnosis of bladder cancer.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.